| | Number/mean/median | %/SD/Min–Max |
| Age (mean, SD) | | 58, 5 | ±16, 1 | Gravida (median, Min–Max) | | 5 | 2–8 | Parity (median, Min–Max) | | 4 | 1–7 | BMI (mean, SD) | | 24, 4 | ±2, 3 | Ca 125 (median, Min–Max) | | 24, 5 | 8, 1–264, 2 | Cigarette (mean, SD) | Pack/year | 12, 1 | ±9, 5 | Mode of delivery | NVD | 7 | 22, 2 | C/S | 2 | 77, 8 | Education status | Illiterate | 5 | 55, 6 | Primary school ≤ | 4 | 44, 4 | Smear result | Absent | 5 | 55, 6 | Normal | 2 | 22, 2 | HSIL | 2 | 22, 2 | First complaint | Postcoital bleeding | 3 | 33, 3 | Pelvic pain | 2 | 22, 2 | Postmenopausal bleeding | 3 | 33, 3 | Vaginal discharge | 1 | 11, 1 | Histological type | Neuroendocrine | 9 | 1, 98 | Others | 444 | 98, 01 | Stage | Early | 3 | 33, 1 | Locally advance | 5 | 55, 5 | Metastatic | 1 | 11, 1 | Stage subgroup (FIGO) | 1b2 | 3 | 33, 3 | 2b | 4 | 44, 4 | 3c2r | 1 | 11, 1 | 4b | 1 | 11, 1 | Treatment modality | Primary CRT | 3 | 33, 1 | Surgery + adj. CRT | 6 | 66, 6 | L/S | Done | 2 | 22, 2 | Not done | 7 | 77, 8 | LVSI status | Negative | 2 | 22, 2 | Positive | 7 | 77, 8 | Lymph status | Negative | 6 | 66, 7 | Positive | 3 | 33, 3 | Recurrence | Present | 3 | 33, 3 | Absent | 6 | 66, 7 | Death | Present | 5 | 55, 6 | Absent | 4 | 44, 4 | Follow-up (month) | | 26 (6–208) | |
|
|
FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index; NVD, normal vaginal delivery; CS, caesarean section; CRT, chemoradiotherapy treatment; and LVSI, lymphovascular space involvement.
|